Research is a chief mission of the Penn Memory Center. We offer a wide range of studies for older adults with memory problems and those with normal cognition. These include:
ADC Logitudinal Research Study
The largest, most comprehensive longitudinal (conducted over time) research effort in the US aimed at better understanding AD, MCI, and lifelong brain health.
Those with normal memory and thinking, MCI, or early to moderate AD may be eligible. One visit, running 2-3 hours, annually.
The purpose of the ASL-PET study is to determine the value of a special MRI scan that measures cerebral blood flow (called Arterial Spin Labeled MRI) in the diagnosis of Mild Cognitive Impairment. We will compare this measure with other more established tests: brain imaging with Postiron Emission Tomography (PET/CT) and a lumbar puncture (LP) procedure, which allow researchers to evaluate the quantity of proteins associated with Alzheimer’s Disease.
Individuals 55-89 years of age with a diagnosis of Mild Cognitive Impairment (MCI) or normal controls may be eligible.
The Generation Study is a phase II/III clinical trial to test whether the drug CAD106 prevents Alzheimer’s disease. Cognitively normal individuals 60-75 years of age with an increased genetic risk of developing Alzheimer’s disease may be eligible. CAD106 is an investigational drug and is not FDA-approved.
Eligible participants will have two copies of the APOE 4 gene. If you do not know your genotype and are interested in learning more about how you may be eligible for the study, please visit the GeneMatch Study website at https://www.endalznow.org/genematch. GeneMatch is a research program of the Alzheimer’s Prevention Registry for people interested in participating in The Generation Study and other Alzheimer’s research studies based on their genetic information.
The Biogen study is a Phase II clinical research study of the drug aducanumab for individuals age 50-85 with early Alzheimer’s disease, including mild cognitive impairment.
Aducanumab is a human antibody that recognizes some forms of beta-amyloid. The primary objective of the study is to evaluate the efficacy of aducanumab in slowing cognitive and functional impairment. This drug is not FDA-approved and is investigational.
Click here for a one-page handout on Biogen.
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 for short), is a clinical research study for older individuals who may be at risk for Alzheimer’s disease (AD). The A4 study is investigating a drug intervention, solanezumab, and Individuals 65-85 years of age with normal cognition may be eligible. The study requires infusion visits every four weeks, for a total of 42 infusion visits over three consecutive years.